HSBC Securities initiated coverage of KKR with a rating of Buy and set a new price target of $148.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2024 | $148.00 | Buy | HSBC Securities |
| 9/12/2024 | $130.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $153.00 | Buy | Redburn Atlantic |
| 1/4/2024 | $96.00 | Outperform | TD Cowen |
| 11/30/2023 | $91.00 → $94.00 | Outperform | Oppenheimer |
| 10/5/2023 | $75.00 | Outperform | Wolfe Research |
| 5/19/2023 | $69.00 | Buy | Citigroup |
| 3/2/2023 | $69.00 | Overweight | Barclays |
KKR Continues to Be Committed to FUJI SOFT's Privatization; Will Not Withdraw its Second Tender Offer KKR, a leading global investment firm, announced today that in connection with the Second Tender Offer in its two-stage tender offer scheme (the "Tender Offer") for the common shares and share options of FUJI SOFT INCORPORATED ("FUJI SOFT" or the "Company"; TSE stock code 9749) through FK Co., Ltd. (the "Offeror" or "FK Co."), an entity owned by investment funds managed by KKR, the Offeror has submitted an amendment statement to the Tender Offer Registration Statement that was submitted on November 20, 2024 (including the matters amended in the amendment statement to the Tender Offer Regi
Biosynth, a global supplier of critical raw materials and services to the life sciences industry, today announced that its Board of Directors has appointed Matt Gunnison as the company's new Chief Executive Officer and a member of the Board of Directors, effective immediately. The Board has also appointed Kieran Murphy as Chairman, effective as of the same date. Matt Gunnison will succeed Urs Spitz, under whose guidance Biosynth has achieved remarkable growth and strengthened its position in the life sciences sector. Urs Spitz will remain a member of the Board of Directors. "We are grateful to Urs for his significant contributions in shaping Biosynth into the innovative and thriving compa
New leadership and reorganization will foster the next chapter of growth and enhance business operations to best support evolving client and CRO partner needs on a global scale. MALVERN, Pa., Oct. 29, 2024 /PRNewswire/ -- Resolian, a leading global bioanalytical and analytical sciences partner supporting drug development and multi-regional clinical trials, today announced several leadership changes as the company expands its global footprint and operational capabilities. Rob Stachlewitz will join Resolian as Chief Executive Officer (CEO), while current CEO Pat Bennett will transition into the newly created role of Chief Business Officer and President of Scientific Affairs. In addition, the
8-K - KKR & Co. Inc. (0001404912) (Filer)
10-Q - KKR & Co. Inc. (0001404912) (Filer)
8-K - KKR & Co. Inc. (0001404912) (Filer)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
HSBC Securities initiated coverage of KKR with a rating of Buy and set a new price target of $148.00
Wells Fargo initiated coverage of KKR with a rating of Equal Weight and set a new price target of $130.00
Redburn Atlantic initiated coverage of KKR with a rating of Buy and set a new price target of $153.00
ForeStructured Growth II innovates RILA market with growth and exclusive yield opportunities, provides an element of built-in loss protection Global Atlantic Financial Group (Global Atlantic), a leading insurance provider meeting the retirement and life insurance needs of individuals and institutions, today announced the launch of ForeStructured Growth II, an innovative registered index-linked annuity ("RILA") designed to help balance growth potential with an element of downside protection. This next-generation RILA solution offers more than 50 index-linked strategies providing a variety of buffer and floor protection features along with the opportunity to grow assets with the index cre
The Company is a leading AI solutions provider across inpatient and outpatient operations, continuing to drive millions of dollars in ROI for health systems partners for over a decade The investment supports development and expansion of first-to-market AI Operational Assistants, extending the platform even further across clinical operations Qventus, a leading provider of AI-based care automation software for health systems, today announced a $105 million investment led by global investment firm KKR, with additional participation from world-renowned investment firm Bessemer Venture Partners, and new strategic investors, including leading health systems Northwestern Medicine, HonorHeal
KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the fourth quarter 2024 on Thursday, February 6, 2025, before the opening of trading on the New York Stock Exchange. A conference call to discuss KKR's financial results will be held on Thursday, February 6, 2025 at 10:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast wi
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Reporting)
KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the fourth quarter 2024 on Thursday, February 6, 2025, before the opening of trading on the New York Stock Exchange. A conference call to discuss KKR's financial results will be held on Thursday, February 6, 2025 at 10:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast wi
KKR today announced a monetization activity update for the period from October 1, 2024 to December 17, 2024. Based on information available to us as of today, with respect to the period through December 17, 2024, KKR's Asset Management segment has earned total realized performance income, including realized carried interest and realized incentive fees, and total realized investment income in excess of $725 million. Realized carried interest drove over half of our monetization activity quarter-to-date. The quarter-to-date monetization activity is driven by a combination of secondary sales and strategic transactions that have closed quarter-to-date, dividends and interest income, as well as i
FUJI SOFT's advisors, directors, and officers tendered ~90% of their share options Result means any plan to privatize FUJI SOFT will require KKR's support KKR, a leading global investment firm, today announced that in connection with its two-stage tender offer scheme (the "Tender Offer") for the common shares and share options of FUJI SOFT INCORPORATED (TSE stock code 9749; "FUJI SOFT") through FK Co., Ltd. (the "Offeror"), the Offeror, an entity owned by investment funds managed by KKR, completed the first of the two planned tender offers ("First Tender Offer") on November 5. With the completion of the First Tender Offer, the Offeror will become the largest shareholder of FUJI SOFT,